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Arthralgia-associated alphaviruses, including chikungunya virus (CHIKV) and Ross River virus (RRV), pose significant public
health threats because of their ability to cause explosive outbreaks of debilitating arthralgia and myalgia in human populations.
Although the host inflammatory response is known to contribute to the pathogenesis of alphavirus-induced arthritis and myosi-
tis, the role that Toll-like receptors (TLRs), which are major regulators of host antiviral and inflammatory responses, play in the
pathogenesis of alphavirus-induced arthritis and myositis has not been extensively studied. Using a mouse model of RRV-in-
duced myositis/arthritis, we found that myeloid differentiation primary response gene 88 (Myd88)-dependent TLR7 signaling is
involved in protection from severe RRV-associated disease. Infections of Myd88- and TLR7-deficient mouse strains with RRV
revealed that both Myd88 and TLR7 significantly contributed to protection from RRV-induced mortality, and both mouse
strains exhibited more severe tissue damage than wild-type (WT) mice following RRV infection. While viral loads were un-
changed in either Myd88 or TLR7 knockout mice compared to WT mice at early times postinfection, both Myd88 and TLR7
knockout mice exhibited higher viral loads than WT mice at late times postinfection. Furthermore, while high levels of RRV-
specific antibody were produced in TLR7-deficient mice, this antibody had very little neutralizing activity and had lower affinity
than WT antibody. Additionally, TLR7- and Myd88-deficient mice showed defects in germinal center activity, suggesting that
TLR7-dependent signaling is critical for the development of protective antibody responses against RRV.
Mosquito-transmitted alphaviruses cause a variety of diseasestates in animals and humans, ranging from joint and mus-
cle pain to severe neuropathology and encephalitis (17, 50, 65).
Because of the wide distribution of their viral vectors and their
ability to cause explosive outbreaks of debilitating arthralgia and
myalgia, arthralgia-associated viruses such as chikungunya virus
(CHIKV) and Ross River virus (RRV) are considered to be signif-
icant emerging disease threats (19, 23, 28, 51). Though rarely fatal,
alphavirus-induced arthritis can be quite debilitating and can
progress to chronic disease in a significant subset of individuals,
thereby significantly affecting the patients’ quality of life and plac-
ing substantial burdens on health care systems (20).
Several studies have demonstrated that immune pathology
contributes to alphavirus-induced arthritis and myositis (21, 29–
31, 37, 38). Mouse models of arthritogenic alphavirus infection
have implicated inflammatory macrophages and complement in
the development of alphavirus-induced disease (21, 29–31, 38,
39). However, the signaling pathways underlying alphavirus
pathogenesis remain poorly understood, and further character-
ization of the pathways contributing to alphavirus-induced ar-
thritis and myositis may lead to the development of more effective
antiviral therapies to treat affected individuals (19).
Toll-like receptors (TLRs) are pattern recognition receptors that
recognize conserved microbial patterns on pathogens, including bac-
teria, fungi, and viruses (26). Following TLR engagement and stimu-
lation by invading microbes, specific adaptor molecules interact with
the activated TLRs and then initiate downstream signaling cascades
to promote innate immune responses and target the associated infec-
tion (62). Although TLRs have been found to play a role in many
virally induced diseases, usually functioning in a protective capacity,
and certain TLRs (including TLR1, -2, -3, -7, -8, and -9) and the TLR
adaptor molecule myeloid differentiation primary response gene 88
protein (Myd88), have been found to be upregulated during alpha-
virus infection (35, 36, 57), the importance of TLRs in the pathogen-
esis of alphavirus-induced arthritis/myositis has not been elucidated.
To determine whether TLRs influence alphavirus pathogene-
sis, we evaluated the role of Myd88 in a mouse model of RRV-
induced arthritis/myositis. Because Myd88 is essential for signal-
ing by all TLRs except for TLR3 and partial TLR4 signaling, we
chose first to focus our studies on Myd88 to determine whether
RRV-induced disease is impacted by the absence of this central
TLR signaling molecule (42, 55, 60, 62). Here we report that mice
deficient in Myd88 developed more severe disease and RRV-in-
duced mortality than RRV-infected wild-type (WT) C57BL/6J
mice and that TLR7-deficient animals exhibited a phenotype al-
most identical to that of the Myd88-deficient mice during RRV
infection. Moreover, mice deficient in TLR7 produced lower levels
of neutralizing antibodies following RRV infection than WT ani-
mals, suggesting that Myd88-dependent TLR7 signaling is re-
quired for the control of RRV replication and for protection from
severe RRV-induced disease.
MATERIALS AND METHODS
Virus stocks and cells. Viral stocks of the mouse-virulent T48 strain of
Ross River virus (RRV) were generated from the full-length T48 cDNA
clone (generously provided by Richard Kuhn, Purdue University) as pre-
viously described (27). Viral titers were determined by plaque assay on
Vero cells as described below. Fresh and confluent Vero cell monolayers,
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grown in Dulbecco modified Eagle medium (DMEM)-F12 (Gibco) with
10% HyClone fetal bovine serum (FBS), 1% nonessential amino acids, 1%
penicillin-streptomycin, 2.5% NaHCO3 (Gibco), and 1% L-glutamine,
were used for all plaque assay and Plaque reduction neutralization test
(PRNT) assay experiments.
Mouse experiments. C57BL/6J wild-type (WT), TLR7-deficient
(TLR7/), and Myd88-deficient (Myd88/) mice were obtained from
The Jackson Laboratory (Bar Harbor, ME) and bred in house. TLR7/
and Myd88/ mice were both maintained on a C57BL/6 background.
Animal husbandry and experiments were performed in accordance with
all University of North Carolina, Chapel Hill, Institutional Animal Care
and Use Committee guidelines. All mouse studies were performed in a
biosafety level 3 laboratory. Twenty-four-day-old mice were used for all in
vivo studies. Mice were anesthetized with isoflurane (Halocarbon Labo-
ratories) prior to subcutaneous inoculation in the left rear footpad with
103 PFU of virus in phosphate-buffered saline (PBS) diluent in a 10-l
volume. Mock-infected animals were inoculated with PBS diluent alone.
Mice were weighed and monitored daily for clinical disease signs. Disease
scores were determined by assessing grip strength, hind limb weakness,
and altered gait as described previously (39). Briefly, mice were scored on
a scale from 0 to 6, where 0 indicated no disease signs, 1 or 2 indicated
ruffled fur and mild hind limb weakness, 3 or 4 indicated moderate hind
limb weakness and altered gait, 5 indicated severe hind limb weakness and
dragging of hind limbs, and 6 indicated that the mice were immobile
(moribund) and unable to consume adequate amounts of food and water,
thus meeting euthanasia criteria.
Viral titers. To determine viral titers in RRV-infected murine tissues,
mice were anesthetized and sacrificed by exsanguination. Quadriceps tis-
sues were excised and homogenized, and serum was extracted prior to
freezing at 80°C until viral titers were assessed. Viral tissues were thawed
on ice and subsequently diluted in PBS diluent in 10-fold dilutions. After
dilution, 200 l of infected tissue samples were pipetted into each well of
70% confluent Vero cells in duplicate for each dilution. The samples were
incubated on the cells for 1 h at 37°C in a CO2 incubator and gently
agitated every 15 min to ensure a uniform distribution of the inoculum on
the cell monolayer. After incubation, the cells were overlaid with an agar
overlay solution consisting of 50% of 2.5% carboxy methylcellulose
(CMC) (Sigma), 50% 2 modified Eagle medium, 3% FBS, 1% penicil-
lin-streptomycin, 1% L-glutamine, and 1% 1 M HEPES buffer (Media-
tech) and incubated for 48 to 72 h at 37°C in a CO2 incubator. Cells were
then fixed with 4% paraformaldehyde for 24 h and counterstained with a
0.25% crystal violet solution in water, and viral plaques were counted.
Histological analysis. At 10 days postinfection, mice were sacrificed
and perfused with 4% paraformaldehyde, pH 7.3. Excised tissues were
embedded in paraffin, and 5-m sections were prepared. To determine
the extent of inflammation and tissue pathology, tissues were stained with
hematoxylin and eosin (H&E) (39). Stained sections were blinded and
scored for overall inflammatory cell infiltration and tissue damage as de-
scribed previously (39). Both scoring systems utilized a 10-point scale
where a score of 0 to 3 represents no to mild inflammation or damage, 4 to
6 represents moderate inflammation or damage, and 7 to 10 represents
severe inflammation or damage. For the analysis of germinal center (GC)
formation, spleen tissues from WT and TLR7/ mice were stained with
H&E, and stained sections were blinded and scored for the number of GCs
and the number of total follicles within the section. GCs were identified
within each follicle by their characteristic staining pattern of a pale, circu-
lar region surrounded by a darker region containing the mantle and mar-
ginal zones.
Flow cytometry. Mice were inoculated as described above, sacrificed
by exsanguination at the indicated times postinfection, and perfused with
1 PBS. Quadriceps muscles or spleens were dissected, minced, and in-
cubated for 1.5 to 2 h with vigorous shaking at 37°C in digestion buffer
(RPMI, 10% fetal bovine serum, 15 mM HEPES, 2.5 mg/ml collagenase A
[Worthington Biochemical Co.], 17 g/ml DNase I [Roche]). Digested
tissues were pelleted, resuspended in HFA buffer (Hanks balanced salt
solution [Gibco], 1% fetal bovine serum, 0.1% sodium azide), passed
through a 70-m cell strainer, and centrifuged for 8 min at 1,000 rpm.
Cells were resuspended in HFA buffer, and viable cell totals were deter-
mined by trypan blue exclusion. Isolated cells were incubated with various
antibodies, according to the associated staining panel, for 30 min to 1 h at
4°C in fluorescence-activated cell sorter staining buffer (1 Hanks bal-
anced salt solution, 1% fetal bovine serum, 2% normal rabbit serum).
Cells were washed, fixed overnight in 2% paraformaldehyde, and analyzed
on a Cyan cytometer (Becton Dickinson) using Summit software. Isolated
splenocytes from mock-infected animals were prepared similarly and
used for single-color staining controls. The lymphocyte staining panel
included the following antibodies: anti-NK1.1–phycoerythrin (PE) (eBio-
science), anti-CD3–fluorescein isothiocyanate (FITC) (eBioscience),
anti-B220 –PE Texas Red (PETR) (Invitrogen), anti-LCA–PECy5 (eBio-
science), anti-F4/80 –PECy7 (eBioscience), anti-CD4 –Pacific blue (PB)
(Caltag Laboratories), anti-CD8 –Pacific orange (PO) (Invitrogen), anti-
CD49b–allophycocyanin (APC) (eBioscience), and anti-GL7–Alexa 88
(eBioscience). The monocyte staining panel included the following antibod-
ies: anti-Ly6G–FITC (BD Pharmingen), anti-SigLecF–PE (BD Pharmingen),
anti-CD11c–PETR (Invitrogen), anti-LCA–PECy5 (eBioscience), anti-F4/
80–PECy7 (eBioscience), anti-CD11b–eF450 (eBioscience), anti-major his-
tocompatibility complex (MHC) class II–APC (eBioscience), and anti-B220–
eF780 (eBioscience).
The gating strategies were as follows. For the inflammatory leukocytes,
CD11c LCA viable cells were displayed on a histogram of Gr-1 plotted
versus SigLecF. Neutrophils appear as a distinct Gr-1-high population,
and SigLecF cells appear on the other side of the diagonal. The SigLecF
subpopulation is displayed on a histogram of CD11b versus CD11c, where
eosinophils appear as a CD11b-high, CD11c-low group, while resident
macrophages are CD11b low and CD11c high. With neutrophils and
SigLecF-high groups gated out, the remaining CD11c-positive cells are dis-
played on a plot of MHC class II versus B220. The B220-high, MHC class
II-low plasmacytoid dendritic cells (pDCs) are gated out, and the remaining
cells are displayed on a plot of MHC class II versus CD11b; the MHC class
II-low cells are enumerated as monocyte-derived DCs (also referred to as
TIP-DCs in some publications), and MHC class II-high, CD11b-high cells are
classified as inflammatory DCs (or CD11b high DCs). For lymphocyte pop-
ulations, viable lymphocytes (selected by forward/side scatter characteristics)
are plotted on a histogram of CD3 versus autofluorescence, and the CD3
cells are further displayed on a plot of CD4 versus CD8. Lymphocytes that are
both CD19 and B220 are counted as B cells, and those that are both
CD49b and NK1.1 are counted as NK cells.
Type I IFN (IFN-/) bioassay. Alpha/beta interferon (IFN-/) lev-
els in cell culture supernatants were measured by an IFN bioassay as de-
scribed previously (47, 48). Briefly, L929 mouse fibroblasts (ATCC
CCL-1) were seeded into 96-well plates and grown in alpha minimal es-
sential medium (MEM). Samples were diluted 1:5 in MEM, acidified to
a pH of 2.0 for 24 h, and then neutralized to pH 7.4. Samples were then
subjected to UV light for 15 min to inactivate any remaining virus, fol-
lowed by titration of the samples by 2-fold serial dilutions across the
seeded 96-well plate. Twenty-four hours later, encephalomyocarditis vi-
rus was added to each well at a multiplicity of infection (MOI) of 5. At 18
to 24 hpi, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) (Sigma) was added to the plate to assess the viability in
each well. The MTT product produced by viable cells was dissolved in
isopropanol containing 0.4% hydrochloric acid and quantified by absor-
bance readings on a microplate reader at 570 nm. Each plate contained an
IFN- standard (Chemicon or R&D Systems) that was used to determine
the number of international units of IFN-/ per milliliter of the un-
known samples.
PRNT assay. Neutralizing antibody titers were determined by plaque
reduction neutralization test (PRNT) assay on Vero cell monolayers.
Briefly, mouse sera were heat inactivated at 56°C for 30 min in a water bath
and then placed on ice. Identical volumes (200 l) of 2-fold mouse serum
dilutions (1:2) and wild-type RRV (103 PFU virus/ml of PBS diluent) were
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mixed together and incubated at 37°C for 30 min in a water bath. After
incubation, 200 l of serum-virus sample mixture was pipetted into each
well of 70% confluent Vero cells in duplicate for each dilution. The sam-
ples were incubated on the cells for 1 h at 37°C in a CO2 incubator and
gently agitated every 15 min to ensure a uniform distribution of the inoc-
ulum on the cell monolayer. After incubation, the cells were overlaid with
an agar overlay solution consisting of 50% 2.5% CMC (Sigma), 50% 2
modified Eagle medium, 3% FBS, 1% penicillin-streptomycin, 1% L-glu-
tamine, and 1% 1 M HEPES buffer (Mediatech) and incubated for 48 to 72
h at 37°C in a CO2 incubator. Cells were then fixed with 4% paraformal-
dehyde for 24 h and counterstained with a 0.25% crystal violet solution in
water, and viral plaques were counted. Neutralizing antibody titers are
expressed as PRNT50, which is the reciprocal dilution where 50% of the
total number of viral plaques in the virus-PBS diluent samples was re-
duced.
ELISA. RRV-specific antibody titers in sera of infected mice were de-
termined by enzyme-linked immunosorbent assay (ELISA) with inacti-
vated RRV (1 g/ml) on high-binding 96-well plates. The serum was first
diluted 20-fold and then further diluted in 2-fold serial dilutions. The
ELISA antibody titer expressed is the estimated dilution factor that gave
an optical density at 450 nm (OD450) of 0.2 and is derived from nonlinear
regression analysis of the serial dilution curve. Detection of bound anti-
body was done using a horseradish peroxidase (HRP)-conjugated goat anti-
mouse secondary antibody (Abcam, Cambridge, MA) and ABTS [2,2=-azino-
bis(3-ethylbenzthiazolinesulfonic acid)] substrate (Invitrogen).
Antibody affinity ELISA. RRV-specific antibody titers in sera of WT
and TLR7/ infected mice were first determined by ELISA as described
above. Inactivated RRV (1 g/ml) was then plated on high-binding 96-
well plates for 12 to 24 h, and serum was diluted in antibody diluent (PBS
containing 0.05% Tween 20 and 10% Sigma Block) and then plated at a
known dilution across the plate to obtain maximum antibody-antigen
binding and incubated at 4°C for 2 h. Following the serum incubation,
increasing concentrations of sodium thiocyanate (NaSCN) were added to
the plate to serially dissociate the antibody-antigen complexes, followed
by incubation with a conjugated secondary IgG antibody and substrate
incubation as described in “ELISA” above. Values were reported as the
percent maximum total IgG binding at each NaSCN concentration.
Passive serum transfer. Twenty-four-day-old WT and TLR7/ mice
were subcutaneously infected in the left rear footpad with 103 PFU of RRV
and subsequently harvested at day 10 postinfection by exsanguination.
Sera from each strain of infected mice were collected, pooled according to
strain, and heat inactivated at 56°C for 1 h. Twenty-four-day-old naïve
WT mice were then inoculated intraperitoneally with 50 l of the heat-
inactivated WT or TLR7/ antisera. At 1 h after serum transfer, the mice
were subcutaneously infected in the left rear footpad with 103 PFU of RRV
and monitored daily for weight loss and disease signs as described above.
Statistical analyses. Data were analyzed using Prism software (Graph-
Pad Software, Inc.). Comparisons of one-variable data were performed
using a two-tailed unpaired Student t test. Percent starting weights for
WT, TLR7/, and Myd88/ mice were analyzed using a one-way anal-
ysis of variance (ANOVA) with multiple-comparison corrections (a P
value of 0.01 is considered significant). Clinical scores for WT,
TLR7/, and Myd88/ mice were analyzed by Mann-Whitney analysis
with Bonferroni’s correction (a P value of 0.01 is considered signifi-
cant). Bar graphs represent mean values  standard deviations. Signifi-
cant differences are represented as follows unless otherwise indicated: *,
P  0.05; **, P  0.01; ***, P  0.001; and ****, P  0.0001.
RESULTS
Myd88 mediates protection from RRV-induced disease. Previ-
ous studies have shown that the host inflammatory response plays
a major role in the pathogenesis of alphavirus-induced arthritis
and myositis (21, 29–31, 37, 38). To further define the host path-
ways that contribute to alphavirus-induced pathology, we evalu-
ated the role of Toll-like receptors (TLRs) in a mouse model of
RRV-induced arthritis/myositis. Because Myd88 is an essential
adaptor for signaling through multiple TLRs, we evaluated mice
deficient in Myd88 for their susceptibility to RRV-induced in-
flammatory disease (42, 55, 60, 62). Myd88-deficient (Myd88/)
mice were highly susceptible to RRV-induced disease, with
Myd88/ mice developing more severe disease signs, as mea-
sured by weight loss and clinical disease scores, than wild-type
(WT) C57BL/6J animals over the course of infection (Fig. 1A and
B). Consistent with previous studies, RRV-infected WT mice lost
weight between days 6 and 10 postinfection and reached peak
disease scores between days 9 and 10 postinfection (Fig. 1A and B).
FIG 1 TLR7 and Myd88 contribute to protection from RRV-induced disease in vivo. Twenty-four-day-old C57BL/6J wild-type (WT), TLR7/, and Myd88/
mice were subcutaneously infected in the left rear footpad with either PBS diluent (mock) or 103 PFU of RRV and monitored for weight loss (A and C) and clinical
disease (B and D) (n 	 5 to 15 mice/strain/time point). *, P  0.01; **, P  0.001; and ***, P  0.0001.
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Although Myd88/ mice showed a similar disease progression,
they lost more weight and exhibited more severe disease than WT
animals over the course of RRV infection (Fig. 1A and B). Further-
more, while RRV-induced disease is self-limited in WT animals,
with the animals completely recovering from RRV-induced dis-
ease, 100% of Myd88/ mice were moribund by day 10 postin-
fection and had to be euthanized. These results suggest that rather
than contributing to disease pathogenesis, Myd88-dependent sig-
naling plays an essential protective role during RRV infection.
TLR7-deficient mice exhibit a phenotype identical to that of
Myd88-deficient animals. While Myd88 operates as an essential
adaptor molecule for most TLRs, it can also serve as an adaptor for
interleukin-1 (IL-1) and IL-18 receptor signaling (3, 7). There-
fore, it was unclear whether Myd88’s protective effect during RRV
infection reflected a role for a specific TLR or possibly signaling
through the IL-1/IL-18 receptors. To address this question, we
sought to evaluate the roles of specific TLRs in the pathogenesis of
RRV-induced disease. These studies initially focused on TLR7, a
Myd88-dependent TLR that is known to play a role in the antiviral
response against multiple viruses, including single-stranded RNA
viruses (12, 32, 33, 49, 52, 62, 63). When TLR7/ mice were
infected with RRV, they exhibited a phenotype identical to that of
Myd88-deficient animals, with TLR7/ mice losing more weight
and developing more severe disease signs than WT mice (Fig. 1C
and D). RRV-infected WT and TLR7/ mice lost weight between
7 and 10 days postinfection, with TLR7/ mice losing weight at a
higher rate than WT animals (Fig. 1C). WT and TLR7/ mice
reached peak clinical disease scores between days 9 and 10 days
after RRV infection (Fig. 1D). However, mice deficient in TLR7
developed disease more rapidly than WT animals following RRV
infection, and peak disease was more severe, with peak disease
scores in TLR7/ mice (5.7  0.4) being significantly higher than
disease scores in WT animals (4.3  0.2) (Fig. 1D). Similar to the
case for Myd88/ mice, TLR7/ mice became moribund by day
10 postinfection and had to be euthanized. Therefore, although we
cannot rule out a role for other Myd88-dependent TLRs, such as
TLR2, or IL-1/IL-18 receptor signaling in the pathogenesis of RRV
infection, these results indicate that TLR7-dependent signaling
through Myd88 plays a major protective role during RRV infec-
tion.
Tissue damage is enhanced in Myd88- and TLR7-deficient
mice following RRV infection. Because skeletal muscle is a tar-
geted tissue for viral replication, inflammation, and tissue de-
struction following RRV infection (37–39), we evaluated the roles
of TLR7 and Myd88 in protection from RRV-induced tissue dam-
age and inflammation. WT, TLR7/, and Myd88/ mice were
sacrificed at 10 days postinfection, which represents the time of
peak disease in the animals (37–39), and quadriceps tissues were
excised and prepared for histological analysis. As shown in Fig. 2,
TLR7/ and Myd88/ mice showed enhanced tissue damage in
skeletal muscle tissue compared with WT mice following RRV
infection. While mock-infected animals of all strains showed sim-
ilar levels of resident inflammatory cells and intact muscle fibers
in skeletal muscle tissue, muscle tissue from TLR7/ and
Myd88/ mice showed fewer intact muscle fibers and more over-
FIG 2 TLR7- and Myd88-deficient mice show enhanced tissue damage following RRV infection. Twenty-four-day old WT, TLR7/, and Myd88/ mice were
subcutaneously infected in the left rear footpad with either PBS diluent or 103 PFU of RRV. Mice were sacrificed and perfused with 4% paraformaldehyde at 10
days postinfection. Quadriceps muscles were excised and paraffin embedded, and 5-m tissue sections were stained with H&E. (A) Histological analysis of
mock-infected and RRV-infected quadriceps muscles from WT, TLR7/, and Myd88/ mice at day 10 postinfection. Representative images are shown. (B)
Blind scoring of overall inflammatory cell infiltration and damage observed in RRV-infected WT and TLR7/ muscle tissue. (n 	 8 for WT and TLR7/). (C)
Blind scoring of overall inflammatory cell infiltration and damage observed in RRV-infected WT and Myd88/ muscle tissue (n 	 5 [WT] or 3 [Myd88/]).
**, P  0.01; ***, P  0.001.
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all tissue destruction following RRV infection than that from WT
mice, despite similar levels of inflammation (Fig. 2A).
To quantify the extent of inflammation and damage present in
the muscle tissues at 10 days postinfection, histological slides were
blinded and scored using a blind scoring method that assigns
scores based on the presence of inflammatory cell infiltrates and
overall damage in the muscle tissue (Fig. 2B and C). The results of
the blind scoring analyses showed that while WT and TLR7/
mice showed similar levels of inflammatory cell infiltration in
skeletal muscle tissue following RRV infection, there was signifi-
cantly more damage in the quadriceps tissue of TLR7/ mice
than in that of WT mice (Fig. 2B), and this was also observed
following histological scoring of WT and Myd88/ skeletal mus-
cle tissues (Fig. 2C). However, no differences were observed fol-
lowing histological analyses of nontarget tissues, such as the brain
and spinal cord, of WT, TLR7/, and Myd88/ mice at day 10
postinfection (data not shown), suggesting that the enhanced tis-
sue damage observed in TLR7- and Myd88-deficient mice is spe-
cific to RRV-targeted skeletal muscle. These data suggest that
TLR7 and Myd88 play a critical role in protection from severe
skeletal muscle damage following RRV infection.
TLR7 deficiency does not affect macrophage recruitment but
does affect T cell recruitment into RRV-infected muscle tissue.
Previous studies have shown that inflammatory macrophages play
a major role in promoting RRV-induced disease (21, 30, 31). Al-
though the histological scoring analyses revealed similar degrees
of inflammation in the skeletal muscle tissue of WT and TLR7/
mice following RRV infection, we sought to more rigorously
quantify the overall number and composition of inflammatory
cells within the skeletal muscle of RRV-infected TLR7/ and WT
mice. At 5 and 7 days postinfection, WT and TLR7/ mice
showed similar numbers of inflammatory leukocyte cell popula-
tions, including inflammatory macrophages, in RRV-infected
quadriceps tissues as determined by flow cytometry (Fig. 3A and
C). Moreover, total numbers of LCA-positive cells isolated from
RRV-infected muscle tissues were not different in WT and
TLR7/ mice at both 5 and 7 days postinfection (data not
shown). Analyses of infiltrating lymphocytes in the quadriceps
muscle tissues revealed a slight decrease in the total numbers of
lymphocyte cell populations, including B cells and CD4 T cells,
in TLR7/ mice compared to WT mice at 5 and 7 days after RRV
infection (Fig. 3B and D). Additionally, there was a small but
statistically significant decrease in CD3-positive and CD4-positive
T cell populations within TLR7/ mice relative to WT mice at 7
days postinfection (Fig. 3D). Therefore, although TLR7 deficiency
did not have a general effect on inflammatory cell recruitment, it
appears that TLR7 deficiency does affect T cell recruitment into
the inflamed muscle tissue during RRV infection.
Type I IFN production in sera of TLR7- and Myd88-deficient
mice is similar to that in sera of WT mice at early times after
RRV infection. TLR7 is known to play an important role in the
antiviral response against a wide range of viral pathogens, in large
part through its ability to regulate type I IFN responses (8, 14, 32,
54, 64, 66). Because type I IFN receptor signaling is essential for
the control of a number of alphaviruses (5, 11, 16, 45, 61), includ-
ing RRV (R. Shabman and M. T. Heise, unpublished data), we
FIG 3 Inflammatory cell recruitment is similar in WT and TLR7/ mice following RRV infection. Twenty-four-day-old WT and TLR7/ mice were
subcutaneously infected in the left rear footpad with 103 PFU of RRV. At 5 and 7 days postinfection, mice were sacrificed and perfused with 1 PBS. Quadriceps
muscles were excised, digested, and prepared for flow cytometric analysis as described in Materials and Methods. (A and C) Total numbers of infiltrating
inflammatory leukocyte cell populations isolated from RRV-infected WT and TLR7/ quadriceps muscle tissue. (B and D) Total numbers of infiltrating
lymphocyte cell populations isolated from RRV-infected quadriceps muscle tissue (n 	 4 to 7 mice/strain/time point). *, P  0.01.
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evaluated whether TLR7 was required for the early regulation of
type I IFN responses in vivo. As shown in Fig. 4, there were no
differences in type I IFN production between WT and TLR7-de-
ficient animals at 12, 24, and 48 h postinfection as measured by
type I IFN bioassay (Fig. 4A). Moreover, type I IFN production
was similar in WT and Myd88/ mice at 24 and 48 h postinfec-
tion (Fig. 4B), suggesting that the early type I IFN response does
not contribute to the enhanced disease phenotype observed in
TLR7- and Myd88-deficient mice following RRV infection.
Viral titers are elevated in mice lacking TLR7 or Myd88 at late
times postinfection. To determine whether the viral burden was
altered in mice deficient in TLR7 or Myd88, we quantified the
amount of virus present in the quadriceps muscles and sera of WT,
TLR7/, and Myd88/ mice at various times after RRV infec-
tion. No significant differences in viral titer were detected in the
quadriceps muscles or sera of WT, TLR7/, and Myd88/ mice
at early times postinfection (Fig. 5). WT and TLR7/ mice did
not show significant differences in viral titer in the quadriceps
muscles by plaque assay at days 0.5, 1, 2, and 3 postinfection (Fig.
5A). However, viral titers in the sera of TLR7/ mice were sig-
nificantly enhanced over those in WT mice at day 3 postinfection
(Fig. 5B), and analysis of the viral burden in infected quadriceps
tissues at later times postinfection revealed that TLR7/ mice
had significantly higher viral titers than WT mice at days 5 and 7
postinfection (Fig. 5A). Similar results were found in Myd88-de-
ficient mice (Fig. 5C and D). Viral titers in the quadriceps were
similar at day 10 postinfection in WT, TLR7/, and Myd88/
mice (Fig. 5A and C), with all samples being close to or below the
limit of viral detection. Therefore, these findings suggest that RRV
is able to infect and spread within target tissues of TLR7/ and
Myd88/ mice with kinetics similar to those in WT animals early
during infection, but mice lacking TLR7 or Myd88 exhibit delayed
control of viral replication within the muscle tissue at later times
postinfection. Although RRV-induced disease is characterized by
FIG 4 Type I IFN production in sera of TLR7/ and Myd88/ mice is similar to that in sera of WT mice early during infection. Twenty-four-day-old WT,
TLR7/, and Myd88/ mice were subcutaneously infected in the left rear footpad with 103 PFU of RRV. At the indicated time points, mice were sacrificed by
exsanguination and serum was collected. Serum was diluted 1:5 in medium and analyzed for the presence of type I IFN (IFN-/) by IFN bioassay as described
in Materials and Methods. (A) Type I IFN production in sera of WT and TLR7/ mice. (B) Type I IFN production in sera of WT and Myd88/ mice (n 	 3
to 5 mice/strain/time point).
FIG 5 Mice lacking TLR7 or Myd88 show an inability to control viral titer at late times postinfection. Twenty-four-day-old WT, TLR7/, and Myd88/ mice
were subcutaneously infected in the left rear footpad with 103 PFU of RRV. At the indicated time points, mice were sacrificed by exsanguination and quadriceps
tissues were dissected. Infectious virus present in homogenized ipsilateral quadriceps tissue (A and C) and serum (B and D) was quantified by plaque assay on
Vero cells (n 	 4 to 8 mice/strain/time point). *, P  0.05; **, P  0.01; ***, P  0.001.
Neighbours et al.
10680 jvi.asm.org Journal of Virology
high levels of viral replication within joint and muscle tissues, with
subsequent overactive inflammatory responses in these tissues
contributing to disease pathogenesis (31, 37–39), the inability of
TLR7- or Myd88-deficient mice to control viral replication at late
times postinfection raised the possibility that the enhanced dis-
ease/mortality in these mice might be due to enhanced viral rep-
lication in other tissues, such as the central nervous system (CNS).
However, we observed no differences in viral load within the
brains and spinal cords of WT and TLR7/ mice at 1 and 2 days
postinfection, and viral titers in these tissues were below the limit
of detection for both mouse strains by day 7 postinfection (data
not shown). We also observed no differences in viral titer in the
kidneys, livers, spleens, and draining lymph nodes between WT
and TLR7/ mice at 1 and 2 days postinfection (data not shown),
suggesting that excess viral replication within the CNS or other
tissues that are not targets of RRV infection does not explain the
enhanced disease observed in TLR7-deficient mice.
TLR7/ mice show reduced neutralizing antibody produc-
tion and decreased antibody affinity following RRV infection.
Because TLR7/ mice showed enhanced viral titers compared to
WT mice at late times postinfection, we hypothesized that defi-
ciency in TLR7 signaling may result in an ineffective antibody
response that leads to an inability to control viral replication dur-
ing RRV infection. To determine whether deficiency in TLR7 af-
fected antibody production following RRV infection, RRV-spe-
cific antibody levels in the sera of WT and TLR7/ mice were
quantified by ELISA at 7 and 10 days postinfection (Fig. 6A and B).
TLR7/ mice showed increased RRV-specific total IgG produc-
tion at 7 and 10 days postinfection compared with WT animals
(Fig. 6A and B), with TLR7/ mice having significantly increased
total RRV-specific IgG at day 7 postinfection (Fig. 6A). Addition-
ally, analysis of RRV-specific IgG subtypes revealed that TLR7/
mice showed significantly increased IgG1 and IgG2c antibody
production at 7 days postinfection, as well as increased IgG2c
antibody levels at day 10 postinfection, relative to WT mice (Fig.
6A and B). These results suggest that RRV-specific antibody pro-
duction is elevated in TLR7/ mice following RRV infection.
Furthermore, because IgG1 is indicative of T-helper 2 (Th2) im-
mune responses and IgG2c is indicative of T-helper 1 (Th1) im-
munity, analysis of RRV-specific IgG subtypes reveals that
TLR7/ mice have a skewed Th1/Th2 antibody response follow-
ing RRV infection relative to WT mice (Fig. 6A and B) (40, 41, 43).
To determine whether the quality of RRV-specific antibody
was altered in TLR7-deficient mice, we first tested the neutraliza-
tion capacities of WT and TLR7/ antisera from 7 and 10 days
after RRV infection by PRNT assay (Fig. 5C). Antisera from
TLR7/ mice had significantly less neutralization activity than
WT antisera at both 7 and 10 days postinfection, suggesting that
the quality of RRV-specific antibody produced by TLR7-deficient
mice is defective and it is less neutralizing than WT antibody re-
sponses following RRV infection (Fig. 6C). To further assess the
quality of RRV-specific antibody in TLR7/ mice, we deter-
mined whether TLR7 deficiency altered the affinity of RRV-spe-
cific antibody using an affinity ELISA (Fig. 7A). As shown in Fig. 7,
RRV-specific IgG from infected TLR7/ mice displayed less af-
finity for RRV than WT IgG, suggesting that TLR7 deficiency af-
fects the affinity maturation of virus-specific antibody during
RRV infection.
Lastly, we directly tested whether sera from RRV-infected
TLR7/ mice showed a reduced capacity to protect from RRV-
induced disease in adoptive transfer studies. We passively trans-
ferred heat-inactivated sera obtained from WT or TLR7/ mice
at day 10 postinfection to naïve WT mice prior to RRV infection.
As shown in Fig. 7, the transfer of TLR7-deficient antisera failed to
FIG 6 TLR7/ mice show reduced neutralizing antibody production following RRV infection. Twenty-four-day-old WT and TLR7/ mice were subcuta-
neously infected in the left rear footpad with 103 PFU of RRV. (A and B) At 7 and 10 days postinfection, mice were sacrificed by exsanguination and serum
antibody levels were measured by ELISA as described in Materials and Methods. Levels of total RRV-specific IgG, IgG1, and IgG2c antibodies in RRV-infected
WT and TLR7/ mice at day 7 (A) and day 10 (B) are shown. (C) At 7 and 10 days postinfection, mice were sacrificed by exsanguination and sera from
RRV-infected WT and TLR7/ mice was tested for RRV neutralization activity using PRNT assay as described in Materials and Methods. Neutralizing antibody
titers are expressed as the inverse of the dilution where 50% of the virus present was neutralized (PRNT50) for a given sample (n 	 6 mice/strain/time point). *,
P  0.05; **, P  0.01; and ***, P  0.001.
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protect WT mice from RRV infection (Fig. 7B and C). WT mice
that received sera from RRV-infected TLR7/ mice showed sig-
nificantly reduced weight gain and enhanced disease signs be-
tween days 5 and 10 postinfection compared to mice that received
WT antisera, which were protected from RRV-induced disease
(Fig. 7B and C).Taken together, these results indicate that TLR7 is
critically important in the establishment of an effective antibody
response following RRV infection.
Myd88 and TLR7 deficiency alters germinal center develop-
ment following RRV infection. Germinal center (GC) B cells have
been shown to be critical for antibody affinity maturation and for
the development of class-switched neutralizing antibodies (1). Be-
cause RRV-specific antibody responses were defective in TLR7-
deficient mice, we investigated whether GC development was al-
tered in TLR7/ mice during RRV infection. As shown in Fig. 8,
histological analysis of spleens from WT and TLR7/ mice at day
10 postinfection revealed that TLR7/ mice had reduced GC
formation following RRV infection. While RRV-infected WT
mice exhibited abundant GC structures at 10 days postinfection,
GC formation was visibly reduced in TLR7/ mouse spleens
(Fig. 8A). Blind scoring analysis of GC formation also revealed a
reduced percentage of GCs per follicle in TLR7-deficient mice
(Fig. 8B). To determine whether Myd88-dependent TLR7 signal-
ing is important in GC B cell development, we quantified the total
numbers of GC B cells present in the spleens of WT and Myd88/
mice at day 9 after RRV infection by flow cytometry. As shown in
Fig. 8C, Myd88-deficient mice showed significantly reduced
GL7 GC B cells compared to WT mice. These results demon-
strate that Myd88-dependent TLR7 signaling is critical for germi-
nal center development and further indicate the importance of
TLR7 in generating an effective adaptive immune response during
RRV infection.
DISCUSSION
The host inflammatory response is known to play a major role
in the pathogenesis of alphavirus-induced arthritis and myositis,
yet the roles of specific host sensing pathways in regulating these
processes have not been investigated in detail. The studies pre-
sented here demonstrate that TLR7 and its essential adaptor mol-
ecule, Myd88, mediate protection against severe RRV-induced
disease and mortality. Furthermore, both TLR7- and Myd88-de-
ficient mice exhibited a defect in viral clearance, and TLR7/
mice failed to mount effective antibody responses against RRV,
showing both reduced antibody neutralizing activity and reduced
RRV-specific antibody affinity. Moreover, TLR7/ mice show
reduced germinal center formation and Myd88-deficient mice
show reduced germinal center (GL7) B cells compared to those
of WT animals following RRV infection. These results suggest that
TLR7-dependent interactions with the adaptive immune response
play a crucial role in regulating the development of protective
immune responses against RRV. Although we cannot rule out a
role for other Myd88-dependent TLRs, such as TLR2, or IL-1/
IL-18 receptor signaling in RRV-induced disease, these findings
provide new insights into the role that TLR7 plays in alphavirus
pathogenesis by highlighting the importance of this pathway in
regulating antiviral adaptive immunity and by identifying TLR7 as
a possible target for enhancing vaccine-induced immune re-
sponses against alphaviruses.
To our knowledge, TLR7’s role in alphavirus pathogenesis has
not previously been investigated. Because type I IFN receptor sig-
FIG 7 Antibody from TLR7/ mice shows decreased virus-specific affinity and fails to protect from RRV-induced disease. Twenty-four-day-old WT and
TLR7/ mice were subcutaneously infected in the left rear footpad with 103 PFU of RRV. At 10 days postinfection, mice were sacrificed by exsanguination and
serum antibody levels were measured by ELISA as described in Materials and Methods. (A) To measure antibody affinity, inactivated RRV was plated on ELISA
plates and sera were added at a 1:40 dilution across the plate. Levels of total IgG were measured in the presence of increasing concentrations of NaSCN as described
in Materials and Methods. Representative data are shown, where n 	 4 (WT) or 6 (TLR7/) mice. (B and C) Twenty-four-day-old WT mice were intraperi-
toneally inoculated with 50 l of heat-inactivated sera from RRV-infected WT or TLR7/ mice harvested at day 10 postinfection. At 1 h after serum transfer,
mice were subcutaneously infected in the left rear footpad with 103 PFU of RRV and monitored for weight loss (B) and clinical disease (C) (n 	 4 mice/group/time
point). *, P  0.001; **, P  0.0001.
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naling is important for the control of a number of alphaviruses (5,
11, 16, 45, 61), we initially focused our analysis on evaluating
whether TLR7 was required for the early control of RRV infection
or regulation of the type I IFN response in vivo. Somewhat sur-
prisingly, we found no evidence for altered viral loads in either the
serum or skeletal muscle at very early to intermediate times in the
infection process (Fig. 5), nor did we find evidence for enhanced
viral replication in other sites, such as the CNS and other nontar-
get tissues, that might contribute to exacerbated RRV-induced
disease and mortality (data not shown). Furthermore, we found
no evidence that systemic type I IFN responses were decreased in
TLR7- and Myd88-deficient animals at early times postinfection
as measured by type I IFN bioassay (Fig. 4), suggesting that other
innate sensing pathways, such as RIG-I and protein kinase R
(PKR), that are known to be involved in the type I IFN response to
alphaviruses (2, 6, 44, 46), rather than TLR7, may contribute to
the early antiviral response against RRV.
In contrast to our findings that TLR7 was not required for the
early control of RRV replication, we did see significant defects in
the ability of both TLR7- and Myd88-deficient animals to control
RRV replication at late times postinfection. Moreover, although
TLR7/ mice were able to mount RRV-specific antibody re-
sponses, the virus-specific antibody that was produced demon-
strated little neutralizing activity and showed less affinity for RRV
than WT antibody, and TLR7- and Myd88-deficient mice exhib-
ited defects in germinal center formation. Moreover, the passive
transfer of TLR7-deficient antisera failed to protect naïve WT
mice from de novo RRV infection, suggesting that TLR7 plays a
major role in driving the development of protective antibody in
response to RRV. Because Myd88-dependent TLR7 signaling in B
cells has been shown to be important in the development of neu-
tralizing antibodies during retrovirus infection (4), it is possible
that TLR7 signaling is necessary for an effective antibody response
to multiple viral pathogens. In addition to the impact on neutral-
izing antibody responses, we also found that TLR7 deficiency re-
sulted in a reduction in the number of CD4 T cells recruited into
the inflamed muscle tissue (Fig. 3). This observed decrease in T
cell recruitment was not due to a general defect in inflammatory
cell infiltration in the TLR7/ mice, because macrophage re-
cruitment was unaffected. Taken together, these findings provide
further evidence that Myd88-dependent TLR7 signaling plays a
role in regulating multiple aspects of the host adaptive immune
response.
Although it remains to be determined exactly how TLR7 and
MyD88 modulate RRV-induced adaptive immune responses,
Myd88 has been shown to be required for efficient cross-presen-
tation of viral antigens by dendritic cells, where Myd88 deficiency
leads to decreased priming and activation of CD8-positive T cells
during infection (9). Likewise, stimulation of TLR7 signaling dur-
ing vaccination can improve neutralizing antibody production,
and it is possible that TLR7 deficiency may also affect neutralizing
activity and affinity maturation of antibodies during alphavirus
infection (25). Importantly, given TLR7’s importance in regulat-
ing the development of protective anti-RRV responses, these stud-
ies suggest that enhancing TLR7-mediated responses may be ben-
eficial during vaccination against RRV or other alphaviruses.
TLR7 is expressed on a wide variety of cell types, including
macrophages and dendritic cell subsets. Although type I IFN re-
sponses in many cell types, including myeloid dendritic cells, are
independent of Myd88 and therefore TLR7 (15), TLR7 is the ma-
jor driver of type I IFN production by plasmacytoid dendritic cell
(pDCs) in response to viral infection or RNA ligands (18). Because
pDCs are known to express high levels of TLR7 and have been
shown to recognize single-stranded RNA (ssRNA) viruses
FIG 8 TLR7/ mice show reduced germinal center formation following RRV infection. Twenty-four-day-old WT and TLR7/ mice were subcutaneously
infected in the left rear footpad with 103 PFU of RRV. Mice were sacrificed and perfused with 4% paraformaldehyde at 10 days postinfection. Spleens were excised
and paraffin embedded, and 5-m tissue sections were stained with H&E. (A) Histological analysis of mock-infected and RRV-infected spleens from WT and
TLR7/ mice at day 10 postinfection. Representative images are shown. (B) Blind scoring of germinal centers (GCs) per follicle observed in WT and TLR7/
spleens. GCs are indicated by arrows (n 	 3 mice/strain). (C) Twenty-four-day-old WT and Myd88/ mice were subcutaneously infected in the left rear footpad
with 103 PFU of RRV At 9 days postinfection, mice were sacrificed and perfused with 1 PBS. Spleens were excised and prepared for flow cytometric analysis as
described in Materials and Methods. Total numbers of GL7 B cells isolated from RRV-infected WT and Myd88/ mouse spleens are shown (n 	 5
mice/strain). *, P  0.01.
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through TLR7 and Myd88, one potential mechanism for the en-
hanced RRV-induced disease seen in TLR7-deficient mice is
through dysfunctional pDC activity (9, 10, 12, 18). We found no
defect in the ability of pDCs isolated from TLR7-deficient mice to
produce type I IFN in response to RRV infection in vitro (data not
shown), although it is possible that pDCs lacking TLR7 may have
other functional defects during RRV infection that we have not yet
uncovered with our studies. Moreover, as noted above, a recent
study demonstrated the importance of Myd88-dependent TLR7
signaling in B cells for the development of effective neutralizing
antibody production during Friend virus infection (4), and it is
possible that Myd88 and TLR7 deficiency in B cells may affect
neutralizing antibody production during alphavirus infection as
well. Studies are ongoing in our lab to assess whether TLR7 ex-
pression is required for the functional activity of pDCs, B cells, and
other immune cell types in response to RRV infection.
These studies clearly demonstrate that TLR7 is required for
protection from lethal RRV-induced disease and that TLR7 mod-
ulated the development of RRV-specific adaptive immune re-
sponses. However, it is not clear whether the delayed clearance of
RRV infection in TLR7-deficient mice can be directly linked to the
enhanced disease and virus-induced mortality. We have previ-
ously shown that RAG-1-deficient (RAG-1/) mice, which lack
functional T and B cells, are susceptible to RRV-induced disease
(39). However, unlike TLR7-deficient animals, RAG-1/ mice
do not die from RRV-induced disease (39). This suggests that the
lack of a protective adaptive immune response does not predis-
pose mice to RRV-induced mortality. This raises two major pos-
sibilities. The first is whether TLR7 is regulating some aspect of
early virus control, such as type I IFN responses, that we were
unable to detect in our studies. While we cannot rule this possi-
bility out, the fact that we did not observe any major changes in
viral load at early times postinfection argues against this possibil-
ity. It is also possible that some aspect of the nonprotective adap-
tive immune response in TLR7/ animals acts to exacerbate
RRV-induced disease. A similar outcome has been found with
respiratory syncytial virus (RSV) vaccination, where the lack of
Myd88 signaling in response to RSV vaccination results in the lack
of a protective anti-RSV response within the lungs and leads to the
development of vaccine-induced immune pathology (13). This
may be particularly important for RRV, because accumulation of
immune complexes comprised of antibody-bound viral particles
in TLR7-deficient animals could lead to enhanced complement
activation via the classical pathway (56, 58). RRV-mediated in-
flammatory disease has previously been shown to be mediated by
complement activation in a mouse model of infection, and other
arthritic diseases are associated with complement activation as
well (22, 24, 37, 38). Alternatively, the high titers of nonneutraliz-
ing, RRV-specific antibodies present in TLR7-deficient mice
could enhance RRV infection through an antibody-dependent en-
hancement (ADE) mechanism, resulting in increased Fc-medi-
ated uptake of antibody-bound viral particles by phagocytic cells
(53). ADE has previously been reported to enhance RRV infection
of macrophages in vitro, and this mechanism could explain the
increased viral titers observed in TLR7- and Myd88-deficient an-
imals at late times after RRV infection, correlating with the onset
of adaptive immune responses (29). Studies are under way to de-
termine whether either of these possible mechanisms contributes
to the enhanced disease and mortality observed in RRV-infected
TLR7/ mice.
In conclusion, the results of this study identify an essential
protective role for the Myd88-dependent TLR7 signaling pathway
during RRV infection and further define the impact of host factors
in the pathogenesis of alphavirus-induced arthritis/myositis.
Given the impact of TLR7 signaling on viral control and on the
generation of protective adaptive immunity following RRV infec-
tion, it may be beneficial to design vaccination and treatment
strategies for alphavirus infections that enhance Myd88-depen-
dent TLR7 signaling, such as through the delivery of TLR7 ago-
nists or through stimulation of downstream signaling molecules,
to ensure optimal protection from alphavirus-induced disease.
Further studies will be necessary to elucidate the mechanism of
TLR7-mediated protection from severe RRV-induced disease.
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